Appendix E - National Coverage Determinations Manual / CARCINOEMBRYONIC_ANTIGEN

Why This Topic Matters

CEA testing is commonly used in cancer surveillance and treatment assessment, so coverage rules can affect ordering patterns, documentation, and medical necessity review. Understanding the scope of this guidance helps users evaluate when the article applies to colorectal and other malignancies.

Article Sections

1. Carcinoembryonic Antigen

   Introduces the biomarker and provides a high-level explanation of its role in monitoring certain malignancies.

2. Indications

   Describes the general clinical circumstances addressed by the coverage guidance, including follow-up and treatment monitoring considerations. It also references an external professional guideline used in the discussion.

3. Limitations

   Summarizes the general frequency limitations and exceptions discussed in the coverage policy. The section focuses on broad testing constraints in oncology follow-up.